Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
Immunome is seeking a highly experienced and strategic HCP Personal Promotions Marketing Lead to lead the U.S. HCP promotional strategy and drive best-in-class field/personal execution for Varegacestat. This role serves as the primary architect of the brand’s HCP clinical narrative—shaping positioning and claims strategy to enable high-quality, compliant HCP engagement. Reporting to the Marketing Brand Lead, this leader will spearhead development of HCP promotional messaging and campaigns, lead creation of field-facing resources, and partner closely with Sales, Sales Training, Medical, Market Development, Legal, Regulatory, and Commercial Operations to deliver launch readiness and sustained field adoption and execution. Success in this role requires deep commercialization expertise in oncology, strong field acumen, and an ability to operate effectively in an entrepreneurial biotech environment.
Responsibilities
HCP Promotional Strategy and Core Messaging Development
Personal Marketing Tactical Development and Execution
Field Stewardship
Brand Leadership and Operational Excellence
Qualifications
Knowledge and Skills
Washington State Pay Range $198,000—$252,000 USD
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.